CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".
As stated previously by Dr. Phillip Chan, CEO of CytoSorbents, "This up-listing to NASDAQ is a significant corporate milestone for CytoSorbents, and is the latest in a series of important accomplishments for the Company. As we continue to advance our business through the ongoing commercial ramp of CytoSorb® in 28 countries worldwide and a planned pivotal cardiac surgery trial in the U.S., one of our primary objectives is to raise our profile within the investment community. We believe that the NASDAQ listing provides an ideal platform from which to broadly communicate our exciting story to potential investors."
Dr. Chan added, "We are experiencing rapid growth at CytoSorbents, as evidenced by our accelerating year-over-year sales of CytoSorb® and the continued global expansion of our product distribution. We believe we are poised for a solid 2015, building upon this year's momentum in the multi-billion dollar critical care and cardiac surgery markets, while leveraging strong relationships with independent distributors and major strategic partners such as Fresenius Medical Care, Biocon Ltd, and one of the top-four global cardiac surgery companies in the world. We are excited to move ahead as a NASDAQ-listed company."
Researchers boost natural defenses to fight cataracts and delay the need for surgery